159 related articles for article (PubMed ID: 37902220)
1. Early skeletal muscle loss in adolescent and young adult cancer patients treated with anthracycline chemotherapy.
Wooten SV; Wang F; Roth ME; Liu G; Livingston JA; Amini B; Gilchrist SC; Hildebrandt M; Kleinerman ES
Cancer Med; 2023 Nov; 12(22):20798-20809. PubMed ID: 37902220
[TBL] [Abstract][Full Text] [Related]
2. Short-Term Changes in Skeletal Muscle Mass After Anthracycline Administration in Adolescent and Young Adult Sarcoma Patients.
Wooten SV; Roth M; Livingston JA; Hildebrandt MAT; Chandra J; Amini B; Kleinerman ES; Gilchrist SC
J Adolesc Young Adult Oncol; 2022 Jun; 11(3):320-322. PubMed ID: 34388045
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle.
de Lima Junior EA; Yamashita AS; Pimentel GD; De Sousa LG; Santos RV; Gonçalves CL; Streck EL; de Lira FS; Rosa Neto JC
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):615-625. PubMed ID: 27239415
[TBL] [Abstract][Full Text] [Related]
4. Adolescent and young adult Hodgkin lymphoma patients at risk for subcutaneous fat gain during early cancer treatment: a brief report.
Wooten SV; Amini B; Roth M; Leung CH; Wang J; Hildebrandt MAT; Kleinerman E
Leuk Lymphoma; 2024 Jan; 65(1):62-68. PubMed ID: 37878765
[TBL] [Abstract][Full Text] [Related]
5. Quantification of chemotherapy-induced changes in body composition in pediatric, adolescent, and young adult lymphoma using standard of care CT imaging.
Tram NK; Chou TH; Ettefagh LN; Deep K; Bobbey AJ; Audino AN; Stacy MR
Eur Radiol; 2022 Oct; 32(10):7270-7277. PubMed ID: 35947147
[TBL] [Abstract][Full Text] [Related]
6. Impaired Cardiac and Skeletal Muscle Energetics Following Anthracycline Therapy for Breast Cancer.
Gamble DT; Ross J; Khan H; Unger A; Cheyne L; Rudd A; Saunders F; Srivanasan J; Kamya S; Horgan G; Hannah A; Baliga S; Tocchetti CG; Urquhart G; Linke WA; Masannat Y; Mustafa A; Fuller M; Elsberger B; Sharma R; Dawson D
Circ Cardiovasc Imaging; 2023 Oct; 16(10):e015782. PubMed ID: 37847761
[TBL] [Abstract][Full Text] [Related]
7. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
8. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
9. Impact of pectoralis muscle loss on cardiac outcome and survival in Cancer patients who received anthracycline based chemotherapy: retrospective study.
Toama W; Wiederin J; Shanley R; Jewett P; Gu C; Shenoy C; Nijjar PS; Blaes AH
BMC Cancer; 2022 Jul; 22(1):763. PubMed ID: 35831837
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
[TBL] [Abstract][Full Text] [Related]
11. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy.
Tsai HR; Gjesdal O; Wethal T; Haugaa KH; Fosså A; Fosså SD; Edvardsen T
Am J Cardiol; 2011 Feb; 107(3):472-7. PubMed ID: 21257017
[TBL] [Abstract][Full Text] [Related]
12. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
13. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
Chia PL; Chiang K; Snyder R; Dowling A
J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
[TBL] [Abstract][Full Text] [Related]
14. Chronic doxorubicin administration impacts satellite cell and capillary abundance in a muscle-specific manner.
D'Lugos AC; Fry CS; Ormsby JC; Sweeney KR; Brightwell CR; Hale TM; Gonzales RJ; Angadi SS; Carroll CC; Dickinson JM
Physiol Rep; 2019 Apr; 7(7):e14052. PubMed ID: 30963722
[TBL] [Abstract][Full Text] [Related]
15. Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood.
Liu Z; Martin J; Orme L; Seddon B; Desai J; Nicholls W; Thomson D; Porter D; McCowage G; Underhill C; Cranswick N; Michael M; Zacharin M; Herschtal A; Sivasuthan J; Thomas DM
Cancer Chemother Pharmacol; 2018 Nov; 82(5):887-898. PubMed ID: 30206658
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
[TBL] [Abstract][Full Text] [Related]
17. Poor Sit-to-Stand Performance in Adolescent and Young Adult Patients with Sarcoma.
Wooten SV; Amini B; Livingston JA; Hildebrandt MAT; Chandra J; Gilchrist SC; Roth M; Kleinerman E
J Adolesc Young Adult Oncol; 2023 Dec; 12(6):821-827. PubMed ID: 37155195
[No Abstract] [Full Text] [Related]
18. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function.
Tarpey MD; Amorese AJ; Balestrieri NP; Fisher-Wellman KH; Spangenburg EE
J Biol Chem; 2019 Dec; 294(51):19709-19722. PubMed ID: 31690631
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin Combined With Ifosfamide for Sarcoma Induces Muscle Atrophy and Sleep Disruption.
Kinoshita H; Hagiwara Y; Ishii T; Kamoda H; Tsukanishi T; Ohtori S; Yonemoto T
Anticancer Res; 2021 Dec; 41(12):6273-6278. PubMed ID: 34848483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
